This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
by Zacks Equity Research
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.04 in the latest trading session, marking a +1.92% move from the prior day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
by Zacks Equity Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $35.05, marking a +0.34% move from the previous day.
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
by Zacks Equity Research
Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $33.72, moving +0.6% from the previous trading session.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $33.59 in the latest trading session, marking a -1.29% move from the prior day.
Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
by Zacks Equity Research
An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.
Glaxo (GSK) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $34.58, marking a +0.93% move from the previous day.
The Zacks Analyst Blog Highlights Apple, Linde, Marsh & McLennan Companies, GSK and Expedia
by Zacks Equity Research
Apple, Linde, Marsh & McLennan Companies, GSK and Expedia are included in this Analyst Blog.
Top Analyst Reports for Apple, Linde & Marsh & McLennan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Marsh & McLennan Companies, Inc. (MMC).
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
Gilead (GILD) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
by Zacks Equity Research
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
by Zacks Equity Research
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
by Zacks Equity Research
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
by Zacks Equity Research
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
GSK (GSK) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?